Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

In this study, Dodatek A operationalizes the Functional Androgen Axis framework by defining three system-level indices and an efficiency metric to describe androgen function, incorporating key methodological improvements and acknowledging significant limitations for future empirical validation.

This article appears to be a table of contents or navigation page for a journal, not presenting any new findings or research results.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

The LTF gene may help predict and manage nonspecific orbital inflammation.

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This study found that combining oral isotretinoin with topical treatments was more effective than topical treatments alone for improving frontal fibrosing alopecia symptoms, despite some side effects.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

This study suggests that infrared thermography may be a useful noninvasive tool for diagnosing active phases of frontal fibrosing alopecia when combined with dermoscopy.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

This study presents a validated questionnaire, the FFA-QLI, which effectively assesses and differentiates the quality of life impact among patients with frontal fibrosing alopecia, showing greater sensitivity in identifying severe cases than the DLQI.

This case study demonstrated that off-label tofacitinib treatment led to full regrowth of scalp hair after 18 months in a patient with alopecia areata universalis, following unsuccessful therapies.

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

This review discusses the regulation of the MiT-TFE family transcription factors, particularly TFEB, through phosphorylation-mediated subcellular localization and reports no new clinical results.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This study found that trans-3,4'-Dimethyl-3-hydroxyflavanone reduces active TGF-beta2 levels in human keratinocytes, suggesting it may enhance hair growth by suppressing the TGF-beta2 activation pathway.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

This study reported that prompt diagnosis and treatment with 5-alpha-reductase inhibitors and topical immunomodulators are key to mitigating the effects of frontal fibrosing alopecia and preventing permanent hair loss.

Early diagnosis of frontal fibrosing alopecia is crucial to prevent permanent hair loss.

In this study, researchers analyzed trichoscopy findings in black patients with FFA to aid in precise diagnosis and treatment, highlighting the importance of understanding disease characteristics to improve hair care in this group.

This study observed that tofacitinib therapy over about 16 weeks had a positive effect in children with alopecia areata, reducing the SALT index significantly in some patients.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

In this study, researchers found that the health state utility of moderate facial angiofibroma in Tuberous Sclerosis Complex patients is significantly lower compared to almost-clear facial angiofibroma, indicating that treatment for the condition can substantially improve quality of life.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.